Future Directions in Cardiac Amyloidosis
References
- Judge DP, Heitner SB, Falk RH, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012
- Huda A, Castano, A, Niyogi A, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. 2021 May 11;12(1):2725. doi: 10.1038/s41467-021-22876-9
- Saad JM, Ahmed AI, Anugula D, Han Y, Alfawara MS, Al-Mallah MH. It Takes a Village: Multimodality Imaging of Cardiac Amyloidosis. Methodist DeBakey Cardiovasc J. 2022 Mar;18(2). In publication.
- Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of Clinical, Echocardiographic and Electrocardiographic Features of Cardiac Amyloidosis to the Presence of the Transthyretin V122I Allele in Older African-American Men. Am J Cardiol. 2011 Aug 1;108(3):440-4. doi: 10.1016/j.amjcard.2011.03.069
- Stern LK, Patel J. Cardiac Amyloidosis Treatment. Methodist DeBakey Cardiovasc J. 2022 Mar;18(2). In publication.
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2021.
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis ; 2017 Nov 8 [cited 2021 Dec 10]. Available from:https://clinicaltrials.gov/ct2/show/NCT03336580 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2021.
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy ; 2020 Apr 24 [cited 2021 Dec 10]. Available from:https://ClinicalTrials.gov/show/NCT04360434 - Gillmore JD, Gane E, Taubel J, et al. CCRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454
- Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. J Am Coll Cardiol. 2016 Jun 28;67(25):2941-8. doi: 10.1016/j.jacc.2016.03.593
- Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631
- Sidiqi MH, Al Saleh AS, Leung N, et al. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J. 2020 May 11;10(5):55. doi: 10.1038/s41408-020-0321-6
- Valent J, Silowsky J, Kurman MR, eet al. Cael-101 is well-tolerated In Al Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (Cybord): A Phase 2 Dose-Finding Study (Nct04304144). Paper presented at: 62nd ASH Annual Meeting and Exposition;
2010 Dec 6 ; Washington, DC. - Chandrashekar P, Desai AK, Trachtenberg BH. Targeted treatments of of AL and ATTR amyloidosis. Heart Fail Rev. 2021 Nov 16. doi: 10.1007/s10741-021-10180-z. Online ahead of print.
- Muchtar E, Therneau TM, Larson, DR, et al. Comparative analysis of staging systems in AL amyloidosis. Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z
- Saelices L, Chung K, Lee JH, et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. PNAS. 2018 Jul 17;115(29):E6741-E6750. doi: 10.1073/pnas.1805131115
DOI: https://doi.org/10.14797/mdcvj.1071 | Journal eISSN: 1947-6108
Language: English
Page range: 73 - 77
Submitted on: Dec 3, 2021
Accepted on: Feb 2, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 Barry Trachtenberg, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.